The association between SGLT2i use and kidney stone risk was similar by race and ethnicity, sex, obesity, and history of chronic kidney disease. Use of an SGLT2 inhibitor instead of other classes of glucose-lowering agents is associated with lower kidney stone risk.
Adult patients with type 2 diabetes (T2D) who use a sodium-glucose cotransporter 2 inhibitor (SGLT2i) rather than other classes of glucose-lowering agents Use of an SGLT2 inhibitor instead of other classes of glucose-lowering agents is associated with lower kidney stone risk.
Use of an SGLT2 inhibitor instead of other classes of glucose-lowering agents is associated with lower kidney stone risk. Use of an SGLT2 inhibitor instead of other classes of glucose-lowering agents is associated with lower kidney stone risk.
Diabetes medication class tied to lower risk of kidney stones medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.